VSTM (VSTM) revenue breakdown
By product, Sale of COPIKTRA license and related assets is the largest at 70% of fiscal 2021 revenue; Transition Services Revenue grew fastest, 63% a year over 1 years.
Revenue by product
Fiscal years, as VSTM reports them in its 10-K filings; fiscal 2021 total $2M.
| Products | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|
| Sale of COPIKTRA license and related assets | — | — | $70M | $1M | 70% |
| Transition Services Revenue | — | — | $372,000 | $606,000 | 30% |
| Product revenue, net | — | — | $15M | — | — |
| Product revenue, net | $2M | $12M | — | — | — |
| License and collaboration revenue | $25M | $5M | — | — | — |
| License and collaboration revenue | — | — | $3M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VSTM.
Open VSTM in InvestinglyQuestions
Where does VSTM make its money?
In fiscal 2021, by product: Sale of COPIKTRA license and related assets $1M, Transition Services Revenue $606,000.
From VSTM's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.